Shares of CytomX Therapeutics Inc. (NASDAQ:CTMX) fell 2.3% on Tuesday . The company traded as low as $9.92 and last traded at $10.10, with a volume of 78,774 shares. The stock had previously closed at $10.34.

CTMX has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 10th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of CytomX Therapeutics in a research note on Tuesday, May 10th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $19.00.

The company has a 50-day moving average price of $10.14 and a 200-day moving average price of $12.21. The stock’s market capitalization is $360.87 million.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Friday, May 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.18.

In other CytomX Therapeutics news, Director Ix L.P. Canaan sold 8,687 shares of the firm’s stock in a transaction that occurred on Friday, May 20th. The shares were sold at an average price of $10.10, for a total transaction of $87,738.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Timothy M. Shannon sold 48,427 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $10.07, for a total transaction of $487,659.89. Following the transaction, the director now owns 134 shares of the company’s stock, valued at approximately $1,349.38. The disclosure for this sale can be found here.

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.